Ezallor Sprinkle

  • Hyperlipoproteinemias

Ezallor Sprinkle Generic Name & Formulations

General Description

Rosuvastatin (as calcium) 5mg, 10mg, 20mg, 40mg; caps.

Pharmacological Class

HMG-CoA reductase inhibitor.

How Supplied

Caps 5mg, 10mg, 20mg, 40mg—30, 90

Generic Availability


Mechanism of Action

Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol.

Ezallor Sprinkle Indications


To reduce risk of MI, stroke, or arterial revascularization procedures in adults without established CHD who are at increased risk of CVD based on age, hsCRP ≥2mg/L, and at least one additional CV risk factor. As an adjunct to diet to reduce LDL-C and slow the progression of atherosclerosis in adults. As an adjunct to diet to reduce LDL-C: in adults with primary hyperlipidemia; or in adults and children aged ≥8yrs with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering treatments (or alone if such treatments are unavailable), to reduce LDL-C in adults and children aged ≥7yrs with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for adults with primary dysbetalipoproteinemia or hypertriglyceridemia.

Ezallor Sprinkle Dosage and Administration


Swallow whole. If unable to swallow caps, can open and sprinkle contents onto applesauce; consume immediately. May be given via NG tube. Take once daily. Dose range 5–40mg. HoFH: initially 20mg. All others: usual starting dose 10–20mg. Use max 40mg dose only if 20mg is insufficient. Asian patients: consider 5mg initially (see full labeling). Concomitant cyclosporine, darolutamide: max 5mg. Concomitant regorafenib, teriflunomide, enasidenib, capmatinib: max 10mg. Concomitant fostamatinib, febuxostat: max 20mg. Concomitant gemfibrozil (if unavoidable), atazanavir/ritonavir, lopinavir/ritonavir, simeprevir, dasabuvir/ombitasvir/paritaprevir/ritonavir, elbasvir/grazoprevir, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir: initially 5mg; max 10mg. Concomitant tafamidis (if unavoidable): initiate at 5mg; max 20mg. Severe renal impairment (CrCl <30mL/min) not on hemodialysis: initially 5mg; max 10mg.


HeFH: <8yrs: not established. 8–<10yrs: usual range 5–10mg/day; 10–17yrs: 5–20mg/day. HoFH: <7yrs: not studied. 7–17yrs: 20mg once daily. 

Ezallor Sprinkle Contraindications


Active liver disease or decompensated cirrhosis.

Ezallor Sprinkle Boxed Warnings

Not Applicable

Ezallor Sprinkle Warnings/Precautions


Risk for myopathy and rhabdomyolysis (esp. aged ≥65yrs, uncontrolled hypothyroidism, renal impairment, concomitant use with certain drugs, higher Ezallor dose). Discontinue if elevated CK levels or myopathy occur or if myopathy is suspected; withhold if a high predisposition to development of renal failure secondary to rhabdomyolysis (eg, sepsis, shock, severe hypovolemia, major surgery, trauma, uncontrolled epilepsy, or severe metabolic, endocrine, or electrolyte disorders). Discontinue if immune-mediated necrotizing myopathy is suspected. Monitor liver function before starting therapy and as clinically indicated. Discontinue promptly if serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs. History of liver disease or heavy alcohol ingestion. Severe renal impairment. Hypothyroidism (if inadequately treated). Asian patients (see Adult dose). Elderly. Pregnancy: discontinue when recognized. Nursing mothers: not recommended.

Ezallor Sprinkle Pharmacokinetics


In clinical pharmacology studies in man, peak plasma concentrations of rosuvastatin were reached 3–5 hours following oral dosing. The absolute bioavailability of rosuvastatin is ~20%.


Mean volume of distribution at steady-state of rosuvastatin is ~134 liters. Rosuvastatin is 88% bound to plasma proteins, mostly albumin.


Rosuvastatin is not extensively metabolized. The major metabolite is N-desmethyl rosuvastatin, which is formed principally by CYP2C9.


Following oral administration, rosuvastatin and its metabolites are primarily excreted in the feces (90%). After an intravenous dose, ~28% of total body clearance was via the renal route, and 72% by the hepatic route. The elimination half-life of rosuvastatin is ~19 hours.

Ezallor Sprinkle Interactions


See Adult dose. Avoid gemfibrozil, tafamidis, sofosbuvir/velpatasvir/voxilaprevir, ledipasvir/sofosbuvir. Increased risk of myopathy and rhabdomyolysis with niacin (≥1g/day), fenofibrates, cyclosporine, darolutamide, regorafenib, teriflunomide, enasidenib, capmatinib, fostamatinib, febuxostat, atazanavir/ritonavir, lopinavir/ritonavir, simeprevir, dasabuvir/ombitasvir/paritaprevir/ritonavir, elbasvir/grazoprevir, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, colchicine; use caution. Monitor INR with warfarin. Caution with drugs that decrease levels or activity of steroid hormones (eg, ketoconazole, spironolactone, cimetidine). Separate dosing of aluminum/magnesium hydroxide combination antacids (give ≥2hrs after rosuvastatin).

Ezallor Sprinkle Adverse Reactions

Adverse Reactions

Headache, myalgia, abdominal pain, asthenia, nausea; myopathy, rhabdomyolysis with renal dysfunction, elevated liver enzymes, proteinuria and hematuria (consider dose reduction if persistent), increased HbA1c and fasting serum glucose, rare: cognitive impairment, hepatic failure.

Ezallor Sprinkle Clinical Trials

See Literature

Ezallor Sprinkle Note

Not Applicable

Ezallor Sprinkle Patient Counseling

See Literature